1. The Rationale for Initiating Treatment of Hypercholesterolemia in Young Adulthood

   • Daniel Steinberg

   Statin Drugs (MB Clearfield, Section Editor) 12 December 2012 Article: 296

2. Moving Beyond JUPITER: Will Inhibiting Inflammation Reduce Vascular Event Rates?

   • Paul M Ridker

   Statin Drugs (MB Clearfield, Section Editor) 09 December 2012 Article: 295

3. Is Atherosclerosis Regression a Realistic Goal of Statin Therapy and What Does That Mean?

   • Mukesh Singh
   • Updesh Singh Bedi

   Statin Drugs (MB Clearfield, Section Editor) 19 December 2012 Article: 294

4. Vitamin D, Calcium, and Atherosclerotic Risk: Evidence from Serum Levels and Supplementation Studies

   • Pamela L. Lutsey
   • Erin D. Michos

   Nonstatin Drugs (WB Borden, Section Editor) 13 December 2012 Article: 293

5. Lipid Effects of Psychiatric Medications

   • Junzo Watanabe
   • Yutaro Suzuki
   • Toshiyuki Someya

   Nonstatin Drugs (WB Borden, Section Editor) 09 December 2012 Article: 292

6. How Do We Improve Patient Compliance and Adherence to Long-Term Statin Therapy?

   • Patricia Maningat
   • Bruce R. Gordon
   • Jan L. Breslow

   Statin Drugs (MB Clearfield, Section Editor) 09 December 2012 Article: 291

7. Does it Make Sense to Combine Statins with Other Lipid-Altering Agents Following AIM-HIGH, SHARP and ACCORD?

   • Willibald Hochholzer
   • Robert P. Giugliano

   Statin Drugs (MB Clearfield, Section Editor) 16 December 2012 Article: 290